Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Italian Journal of Pediatrics
Published in: Italian Journal of Pediatrics 1/2023

Open Access 01-12-2023 | Mononucleosis | Research

Concordance of adenosine deaminase with immunoglobulins and lymphocyte subsets in EBV-related diseases

Authors: Ting Shi, Qi Ding, Xinglou Liu, Guo Ai, Hua Zhou, Linlin Huang

Published in: Italian Journal of Pediatrics | Issue 1/2023

Login to get access

Abstract

Background

Clinical manifestations of Epstein–Barr virus (EBV) infection are diverse. This study aimed to explore the immune response in EBV-related diseases and the correlation between immune cells and adenosine deaminase (ADA) levels.

Methods

This study was conducted at the Children’s Hospital of Soochow University. In total, 104 patients with EBV-associated respiratory tract infection (EBV-RTI), 32 patients with atypical EBV infection, 54 patients with EBV-associated infectious mononucleosis (IM1, with normal alanine aminotransferase [ALT] levels), 50 patients with EBV-IM2 (with elevated ALT levels), 50 patients with acute respiratory infection (AURI, with other pathogens), and 30 healthy controls were enrolled in this study. Indicators of ADA, immunoglobulins (Igs), and lymphocyte subsets were analyzed for EBV-related diseases.

Results

Differences in the white blood cell, lymphocyte counts, ADA levels, IgA, IgG and IgM titers, percentage of CD3+, CD3+CD4+, CD3+CD8+, CD16+CD56+, CD3−CD19+, and CD19+CD23+ lymphocytes, and CD4+/CD8+ ratio between EBV-related disease groups were all statistically significant (P < 0.01). ADA levels in the EBV-related disease groups were significantly higher than those in the control group (P < 0.01). The lymphocyte count, ADA levels, IgA and IgG titers, and percentage of CD3+ and CD3+CD8 + lymphocytes in the atypical EBV infection, EBV-IM1, and EBV-IM2 groups were significantly higher than those in the EBV-RTI, AUTI, and control groups (P < 0.01), whereas the percentage of CD3+CD4+, CD3−CD19+, and CD19+CD23+ lymphocytes and CD4+/CD8+ ratio showed the opposite trend. ADA levels were consistent with and closely related to the viral load and cellular and humoral immunity in EBV-related diseases.

Conclusions

ADA levels, humoral immunity, and cellular immunity were diverse in EBV-related diseases, and ADA was closely related to Igs and lymphocyte subsets.
Literature
1.
2.
3.
Rostgaard K, Balfour HH Jr, Jarrett R, Erikstrup C, Pedersen O, Ullum H, et al. Primary Epstein-Barr virus infection with and without infectious mononucleosis. PLoS ONE. 2019;14:e0226436.CrossRefPubMedPubMedCentral
4.
Kasahara Y, Yachie A. Cell type specific infection of Epstein-Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol Hematol. 2002;44:283–94.CrossRefPubMed
5.
Shi T, Huang L, Chen Z, Tian J. Characteristics of primary Epstein-Barr virus infection disease spectrum and its reactivation in children, in Suzhou, China. J Med Virol. 2021;93:5048–57.CrossRefPubMed
6.
7.
Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis. 2013;207:80–8.CrossRefPubMed
8.
9.
Houssaint E, Saulquin X, Scotet E, Bonneville M. Immunodominant CD8 T cell response to Epstein-Barr virus. Biomed Pharmacother. 2001;55:373–80.CrossRefPubMed
10.
11.
Cortés A, Gracia E, Moreno E, et al. Moonlighting adenosine deaminase: a target protein for drug development. Med Res Rev. 2015;35(1):85–125.CrossRefPubMed
12.
Antonioli L, Colucci R, La Motta C, Tuccori M, Awwad O, Da Settimo F, et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr Drug Targets. 2012;13:842–62.CrossRefPubMed
13.
Mejer J, Nygaard P, Cohn J, Gadeberg O, Faber V. Adenosine deaminase, purine nucleoside phosphorylase and 5’-nucleotidase activities in infectious mononucleosis. Adv Exp Med Biol. 1984;165:249–52. Pt A: 249 – 52.CrossRefPubMed
14.
Shi T, Li J, Miao Y, et al. Adenosine deaminase as a marker for the severity of infectious mononucleosis secondary to EBV in children. BMC Infect Dis. 2022;22:876–85.CrossRef
15.
Shi J, Ma W, Li W. Epidemiologic features of children with Epstein-Barr virus associated diseases in Hangzhou, China. J Med Virol. 2020;92:1277–82.CrossRefPubMed
16.
Odame J, Robinson J, Khodai-Booran N, Yeung S, Mazzulli T, Stephens D, et al. Correlates of illness severity in infectious mononucleosis. Can J Infect Dis Med Microbiol. 2014;25:277–80.CrossRefPubMedPubMedCentral
17.
Jayasooriya S, de Silva TI, Njie-jobe J, Sanyang C, Leese AM, Bell AI, et al. Early virological and immunological events in asymptomatic Epstein-Barr virus infection in african children. PLOS Pathog. 2015;11:e1004746.CrossRefPubMedPubMedCentral
18.
19.
Houen G, Trier NH. Epstein-Barr Virus and systemic Autoimmune Diseases. Front Immunol. 2020;11:587380.CrossRefPubMed
20.
Kakalacheva K, Regenass S, Wiesmayr S et al. Infectious Mononucleosis Triggers Generation of IgG Auto-Antibodies against Native Myelin Oligodendrocyte Glycoprotein. Viruses. 2016. 8(2).
21.
Ben-Chetrit E, Wiener-Well Y, Fadeela A, Wolf DG. Antiphospholipid antibodies during infectious mononucleosis and their long term clinical significance. J Clin Virol. 2013;56(4):312–5.CrossRefPubMed
22.
Sutton RN, Emond RT, Thomas DB, Doniach D. The occurrence of autoantibodies in infectious mononucleosis. Clin Exp Immunol. 1974;17:427–36.PubMedPubMedCentral
23.
Long HM, Chagoury OL, Leese AM, Ryan GB, James E, Morton LT, et al. MHC II tetramers visualize human CD4 + T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. J Exp Med. 2013;210:933–49.CrossRefPubMedPubMedCentral
24.
Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587–617.CrossRefPubMed
25.
Barros MHM, Vera-Lozada G, Segges P, Hassan R, Niedobitek G. Revisiting the tissue microenvironment of infectious mononucleosis: identification of EBV infection in T cells and deep characterization of immune profiles. Front Immunol. 2019;10:146.CrossRefPubMedPubMedCentral
26.
Lam JKP, Hui KF, Ning RJ, Xu XQ, Chan KH, Chiang AKS. Emergence of CD4 + and CD8 + polyfunctional T cell responses against immunodominant lytic and latent EBV antigens in children with primary EBV infection. Front Microbiol. 2018;9:416.CrossRefPubMedPubMedCentral
27.
Hendricks DW, Balfour HH Jr, Dunmire SK, Schmeling DO, Hogquist KA, Lanier LL. Cutting edge: NKG2C(hi)CD57 + NK cells respond specifically to acute infection with cytomegalovirus and not Epstein-Barr virus. J Immunol. 2014;192:4492–6.CrossRefPubMed
28.
Strowig T, Brilot F, Arrey F, Bougras G, Thomas D, Muller WA, et al. Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma. PLOS Pathog. 2008;4:e27.CrossRefPubMedPubMedCentral
29.
Yu DM, Slaitini L, Gysbers V, Riekhoff AG, Kähne T, Knott HM, et al. Soluble CD26 / dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand J Immunol. 2011;73:102–11.CrossRefPubMed
30.
Moreno E, Canet J, Gracia E, Lluís C, Mallol J, Canela EI, et al. Molecular evidence of adenosine deaminase linking adenosine A2a receptor and CD26 proteins. Front Pharmacol. 2018;9:106.CrossRefPubMedPubMedCentral
31.
Lamontagne RJ, Soldan SS, Su C, Wiedmer A, Won KJ, Lu F, et al. A multi-omics approach to Epstein-Barr virus immortalization of B-cells reveals EBNA1 chromatin pionering activities targeting nucleotide metabolism. PLOS Pathog. 2021;17:e1009208.CrossRefPubMedPubMedCentral
Metadata
Title
Concordance of adenosine deaminase with immunoglobulins and lymphocyte subsets in EBV-related diseases
Authors
Ting Shi
Qi Ding
Xinglou Liu
Guo Ai
Hua Zhou
Linlin Huang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue 1/2023
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-023-01457-0

Other articles of this Issue 1/2023

Italian Journal of Pediatrics 1/2023 Go to the issue

Research

GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease

Research

When two Z-scores meet—analysis of exercise capacity of children and adolescents with Kawasaki disease by a new Z-score model of coronary artery and a new Z-score evaluating peak oxygen consumption

Review

The role of the pediatrician in the management of the child and adolescent with gender dysphoria

Research

Association of preterm outcome with maternal systemic lupus erythematosus: a retrospective cohort study

Case report

Report and follow-up on two new patients with congenital mesoblastic nephroma

Review

Dilemmas and options for COVID-19 vaccination in children